CapsoVision, Inc.
4.6750-0.01 (-0.32%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · CV · USD
Key Stats
Market Cap
218.67MP/E (TTM)
-Basic EPS (TTM)
-0.44Dividend Yield
0%Recent Filings
8-K
CFO steps down abruptly
CapsoVision's CFO Kevin Lundquist stepped down effective August 27, 2025, prompting a search for his successor. Under the separation agreement, he receives six months' base salary, a $33,333.33 prorated bonus, accelerated vesting of options for 86,806 shares exercisable until September 1, 2028, and COBRA coverage. Lundquist will consult through February 28, 2026. Leadership transition underway.
8-K
Q2 revenue up 17%
CapsoVision reported Q2 2025 revenue of $3.3 million, up 17% from Q2 2024, fueled by higher CapsoCam Plus sales and 75% growth in new accounts. Gross profit rose to $1.8 million at 55% margin, while operating expenses dipped to $6.5 million, narrowing net loss to $4.6 million. The July IPO injected $23.4 million in net proceeds, bolstering cash from $1.1 million. FDA submission for CapsoCam Colon signals pipeline expansion, yet regulatory risks loom.
10-Q
Q2 FY2025 results
CapsoVision posted solid Q2 revenue growth of 17% year-over-year to $3.3M, driven by higher CapsoCam Plus capsule sales, while gross margin held steady at 55% despite competitive pricing pressures. Operating loss narrowed 12% to $4.7M as R&D costs dropped 20% following completion of the CapsoCam Colon pivotal study, though G&A rose on professional fees. Cash burned $9.5M in H1, leaving $1.1M at quarter-end, with the July IPO netting $23.4M to fund commercialization; free cash flow not disclosed in the 10-Q. The firm filed for initial CapsoCam Colon clearance in June, targeting Q2 2026 launch after second-arm study. Revenue remains tied to small-bowel sales amid regulatory hurdles. Competition from established players like Medtronic poses ongoing market risks.
8-K
Canon sensor development deal
CapsoVision inked a deal with Canon on July 15, 2025, to develop CMOS image sensors for future capsule endoscopes, paying $4.1 million total—$1 million upfront, the rest via added unit prices on future purchases. This bolsters tech for post-FDA clearance products, while underwriters exercised an overallotment option on July 16, netting $600,000 more from 129,978 shares. Future sensors target enhanced evaluations. Delays risk termination.
8-K
IPO closes with $27.5M proceeds
CapsoVision closed its initial public offering on July 3, 2025, selling 5.5 million shares at $5.00 each for $27.5 million in gross proceeds before expenses. The stock began trading on Nasdaq under 'CV' on July 2, while underwriters hold a 30-day option for 825,000 more shares. This influx bolsters the medtech firm's push into AI-driven capsule endoscopy. Lock-ups curb insider sales for six months.
AVNS
Avanos Medical, Inc.
11.43-0.15
BSX
Boston Scientific Corporation
100.30-0.67
CBLL
CeriBell, Inc.
12.03-0.80
CVRX
CVRx, Inc.
10.81+0.09
ECIA
Encision, Inc.
0.35+0.12
ENOV
Enovis Corporation
31.99-0.87
LUCD
Lucid Diagnostics Inc.
1.25-0.02
PAVM
PAVmed Inc.
0.44+0.00
VTAK
Catheter Precision, Inc.
2.44-0.12
VYCO
Vycor Medical, Inc.
0.15+0.00